bioAffinity Technologies (bioAffinity Technologies) EV-to-EBIT : 0.00 (As of Jun. 03, 2024)

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, bioAffinity Technologies's Enterprise Value is $0.00 Mil. bioAffinity Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.30 Mil. Therefore, bioAffinity Technologies's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for bioAffinity Technologies's EV-to-EBIT or its related term are showing as below:

BIAFW' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.21 Med: -1.46 Max: -0.06
Current: -3.16

During the past 4 years, the highest EV-to-EBIT of bioAffinity Technologies was -0.06. The lowest was -3.21. And the median was -1.46.

BIAFW's EV-to-EBIT is ranked worse than
100% of 100 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.05 vs BIAFW: -3.16

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. bioAffinity Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil. bioAffinity Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.30 Mil. bioAffinity Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

bioAffinity Technologies EV-to-EBIT Historical Data

The historical data trend for bioAffinity Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies EV-to-EBIT Chart

bioAffinity Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-0.40

-1.60

bioAffinity Technologies Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial									-0.94	-0.84	-1.11	-1.60	-2.62

Competitive Comparison of bioAffinity Technologies's EV-to-EBIT

For the Diagnostics & Research subindustry, bioAffinity Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's EV-to-EBIT falls into.

bioAffinity Technologies EV-to-EBIT Calculation

bioAffinity Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-8.295
	=	0.00

bioAffinity Technologies's current Enterprise Value is $0.00 Mil.
bioAffinity Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.30 Mil.

bioAffinity Technologies (NAS:BIAFW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

bioAffinity Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-8.295	/	0
	=	%

bioAffinity Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil.
bioAffinity Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.30 Mil.

bioAffinity Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

bioAffinity Technologies (bioAffinity Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAFW) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

BIAF:USA

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.